Two new therapeutic drugs for blood tumors are on the market in China!

Recently, Xi'an Yangsen Pharmaceutical Co., Ltd. announced that a new therapeutic drug for the treatment of two blood tumors, Yiyi (Ibtini capsules), has been officially launched in China. The drug is known to be an oral Bruton tyrosine kinase (BTK) inhibitor and is suitable for patients with chronic lymphocytic leukemia/small lymphocyte lymphoma who have previously received at least one treatment, as well as patients with cell lymphoma who have previously received at least one treatment.
Following the "priority review" of the Drug Review Center of the State Food and Drug Administration in December last year, ibtinib capsules were approved by the State Food and Drug Administration on August 24 this year and were officially launched 69 days after approval, providing an important new treatment option for long-awaited Chinese patients."Chronic lymphocytic leukemia/small lymphocytic lymphoma and set cell lymphoma are two rare diseases, with an estimated annual incidence rate of 0.27/100,000 and 0.16/100,000 in China, respectively," stressed Professor Ma Jun, president of the China Anti-Lymphoma Alliance and director of Harbin Hematic Oncology Institute,
Professor Ma Jun, President of the China Anti-Lymphoma Alliance and Director of Harbin Hematic Tumor Research Institute. The recurrence rate of these two diseases is high, but the current treatment methods are limited. It is worth noting that china has not had new drugs for the treatment of these two diseases in the past 8 years, resulting in drug resistance and recurrence of patients facing adverse prognosis and no drug available situation. As a result, both patients and doctors are eagerly awaiting a new treatment option that is well tolerated and more effective. "
five international Phase II/III trials and an Asia-Pacific Phase III study evaluating the safety and effectiveness of Ibtini capsules for the treatment of chronic lymphocytic leukemia/small lymphocyte lymphoma and cell lymphoma."Clinical trials in Both Chinese patients and international multi-centers have shown that patients with chronic lymphocytic leukemia/small lymphocyte lymphoma who received at least one treatment had a reduced risk of death or progression by about 80 percent after receiving ibutini capsules, meaning that their median survival was close to similar to those of the same age group," said Li Bin, vice president of medical affairs at Xi'an Yangsen Pharmaceutical Co., Ltd.,
.
currently, ibtini capsules cover 49 cities. At the same time, the China Primary Health Care Foundation has launched the "Billion New Life- Lymphoma Patient Assistance Program" to provide ibtinib capsule drug assistance to low-income lymphoma patients. The drug has been approved in 86 countries and has been used in more than 90,000 patients worldwide.
.